Statin use and cancer risk: an epidemiologic review.
While the beneficial effects of hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) on cardiovascular disease are well established, much uncertainty remains about their effects on cancer. The statins inhibit the rate-limiting step in the mevalonate pathway, leading to reduced levels of cholesterol and other molecules of importance for critical cellular processes. A growing body of preclinical data indicates that statins may have antineoplastic properties, but some studies raise the possibility that statins may possess a carcinogenic potential. Clinical and observational studies of the association between statin use and cancer have been inconclusive with regard to any chemopreventive or therapeutic effect, but they do provide reassuring evidence that statins do not appear to be carcinogenic. The reasons for the varying results are unclear but they may relate to methodological issues. Additional studies, including Phase II randomized trials and epidemiological studies with accurate measures of statin use and comprehensive control for confounding factors, are needed to determine the potentially beneficially effects of statins on cancer development and progression.
Friis
Søren
S
Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. friis@cancer.dk
Olsen
Jørgen H
JH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced* / Q000188:drug therapy* / Q000453:epidemiology*; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors